Literature DB >> 8943250

Moving from the orphanin FQ receptor to an opioid receptor using four point mutations.

F Meng1, L P Taylor, M T Hoversten, Y Ueda, A Ardati, R K Reinscheid, F J Monsma, S J Watson, O Civelli, H Akil.   

Abstract

It is unclear how receptor/ligand families that are evolutionarily closely related achieve functional separation. To address this question, we focus here on the newly discovered Orphanin FQ, a peptide homologous to the opioid peptide Dynorphin, and its receptor, the Orphanin FQ receptor, which is highly homologous to the opioid receptors. In spite of this high degree of homology in terms of both ligands and receptors, there is little direct cross-talk between the Orphanin FQ system and the endogenous opioid system. Thus, the opioid peptides show either relatively low affinity or no affinity toward the Orphanin FQ receptor; conversely, Orphanin FQ has no affinity toward any of the opioid receptors. We sought to investigate the molecular basis of such discrimination by attempting to reverse it and endowing the Orphanin FQ receptor with the ability to bind opioids. We report that by mutating as few as four amino acids, we can produce a receptor that recognizes pro-Dynorphin products with very high affinity and yet still binds Orphanin FQ as well as the wild-type receptor. This suggests that the Orphanin FQ receptor has developed features that specifically exclude the opioids and that these features are distinct from those required for the high affinity binding of its own endogenous ligand.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943250     DOI: 10.1074/jbc.271.50.32016

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  In silico study of the structurally similar ORL1 receptor agonist and antagonist pairs reveal possible mechanism of receptor activation.

Authors:  Milan Senćanski; Ljiljana Dosen-Mićović
Journal:  Protein J       Date:  2014-06       Impact factor: 2.371

2.  Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.

Authors:  Michael E Meyer; Arpit Doshi; Dennis Yasuda; Nurulain T Zaveri
Journal:  AAPS J       Date:  2021-05-11       Impact factor: 4.009

3.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

4.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

5.  Nociceptin/orphanin FQ suppresses adaptive immune responses in vivo and at picomolar levels in vitro.

Authors:  Benito Anton; Phillipe Leff; Joseph J Meissler; Juan C Calva; Rodolfo Acevedo; Alberto Salazar; Maura Matus; Anabel Flores; Martin Martinez; Martin W Adler; John P Gaughan; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2010-02-02       Impact factor: 4.147

6.  Molecular basis for the selectivity of the mammalian bombesin peptide, neuromedin B, for its receptor.

Authors:  Nieves González; Tomoo Nakagawa; Samuel A Mantey; Veronica Sancho; Hirotsugu Uehara; Tatsuro Katsuno; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2009-07-23       Impact factor: 4.030

Review 7.  Orphan GPCRs and neuromodulation.

Authors:  Olivier Civelli
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

8.  Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.

Authors:  Nieves Gonzalez; Simon J Hocart; Sergio Portal-Nuñez; Samuel A Mantey; Tomoo Nakagawa; Enrique Zudaire; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2007-11-15       Impact factor: 4.030

9.  Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.

Authors:  Aaron A Thompson; Wei Liu; Eugene Chun; Vsevolod Katritch; Huixian Wu; Eyal Vardy; Xi-Ping Huang; Claudio Trapella; Remo Guerrini; Girolamo Calo; Bryan L Roth; Vadim Cherezov; Raymond C Stevens
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

10.  Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.

Authors:  Nurulain T Zaveri; V Blair Journigan; Willma E Polgar
Journal:  ACS Chem Neurosci       Date:  2015-02-18       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.